Pharmaceutical company Mylan N.V. (Mylan or the company) recently agreed to pay $30 million to settle claims brought by the U.S. Securities and Exchange Commission (SEC) for alleged material misstatements and omissions in the company’s periodic reports.
The SEC complaint alleges that Mylan failed to timely disclose or accrue for liability arising out of an investigation by the Department of Justice (DOJ) into Mylan’s practice of characterizing EpiPen as a generic drug for the purposes of the Medicaid Drug Rebate Program (MDRP). The complaint also alleges that Mylan’s periodic reports contained misleading risk factor disclosures on a related topic.
Sidley Austin LLP provides this information as a service to clients and other friends for educational purposes only. It should not be construed or relied on as legal advice or to create a lawyer-client relationship. Readers should not act upon this information without seeking advice from professional advisers.
Attorney Advertising—Sidley Austin LLP, One South Dearborn, Chicago, IL 60603. +1 312 853 7000. Sidley and Sidley Austin refer to Sidley Austin LLP and affiliated partnerships, as explained at www.sidley.com/disclaimer.
© Sidley Austin LLP